A neuronal network of mitochondrial dynamics regulates metastasis by M.C. Caino et al.
ARTICLE
Received 16 Jun 2016 | Accepted 28 Oct 2016 | Published 19 Dec 2016
A neuronal network of mitochondrial dynamics
regulates metastasis
M. Cecilia Caino1,2, Jae Ho Seo1,2, Angeline Aguinaldo3, Eric Wait3, Kelly G. Bryant1,2, Andrew V. Kossenkov4,
James E. Hayden5, Valentina Vaira6,7,8, Annamaria Morotti7,8, Stefano Ferrero7,9, Silvano Bosari7,8,
Dmitry I. Gabrilovich1,10, Lucia R. Languino1,11, Andrew R. Cohen3 & Dario C. Altieri1,2
The role of mitochondria in cancer is controversial. Using a genome-wide shRNA screen,
we now show that tumours reprogram a network of mitochondrial dynamics operative
in neurons, including syntaphilin (SNPH), kinesin KIF5B and GTPase Miro1/2 to localize
mitochondria to the cortical cytoskeleton and power the membrane machinery of cell
movements. When expressed in tumours, SNPH inhibits the speed and distance travelled
by individual mitochondria, suppresses organelle dynamics, and blocks chemotaxis and
metastasis, in vivo. Tumour progression in humans is associated with downregulation or loss
of SNPH, which correlates with shortened patient survival, increased mitochondrial trafﬁcking
to the cortical cytoskeleton, greater membrane dynamics and heightened cell invasion.
Therefore, a SNPH network regulates metastatic competence and may provide a therapeutic
target in cancer.
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O
ne of the hallmarks of cancer1 is the rewiring
of metabolism from oxidative phosphorylation in
mitochondria to aerobic glycolysis, the so-called
‘Warburg effect’2. This process has been linked to increased
metastatic propensity3, and worse disease outcome, at least in
certain tumours4. However, mitochondria continue to play
an important role in tumour metabolism5, as oxidative
phosphorylation contributes to malignant growth, in vivo6, and
fuels unique tumour traits, including repopulation after oncogene
ablation7, and metastatic dissemination8,9. How these processes
are regulated is unclear, and druggable therapeutic targets of
mitochondrial bioenergetics have remained elusive5.
Recent studies have suggested that mitochondrial metabolism
may couple to mechanisms of organelle dynamics, controlling the
shape, size and topography of mitochondria in tumour cells10.
This may be important to sustain highly energy-intensive
processes, including the ability of tumour cells to invade across
basement membranes11, the antecedent of metastasis12. In this
context, the repositioning of energetically active mitochondria to
the cortical cytoskeleton of tumour cells13 has been proposed as a
‘spatiotemporal’ bioenergetics source to fuel membrane-actin
dynamics, turnover of focal adhesion (FA) complexes, and
increased chemotaxis and invasion14.
In this study, we used a genome-wide short hairpin RNA
(shRNA) screen to identify novel regulators of mitochondrial
function implicated in tumour cell invasion. We found that
tumours exploit a cytoskeletal trafﬁcking network well known
in neurons to concentrate mitochondria at the peripheral
cytoskeleton, and fuel the machinery of cell motility and invasion.
A critical regulator of this network is syntaphilin (SNPH), which
couples the speed of mitochondrial repositioning with cycles of
organelle fusion and ﬁssion to regulate metastatic competence in
mice, and disease outcome in humans.
Results
Novel mitochondrial regulators of tumour cell invasion. Our
previous results demonstrated that inhibition of mitochondrial
oxidative phosphorylation with Gamitrinib, a mitochondrial-
targeted inhibitor of Heat Shock Protein-90 (Hsp90)15 abolished
tumour cell invasion8. To further characterize this pathway, we
carried out a genome-wide shRNA screen for molecules that
rescued Gamitrinib inhibition of tumour cell invasion (Fig. 1a).
Using a cutoff of 500 reads for three independent shRNAs in two
separate experiments (Supplementary Fig. 1a), we identiﬁed 174
genes that restored tumour cell invasion in the presence of
Gamitrinib (Supplementary Table 1). Bioinformatics analysis
grouped these molecules as regulators of cytoskeleton, cell
adhesion, protein kinases, WD repeat proteins and cell motility
(Fig. 1b,c, Supplementary Table 1).
One of the top hits in the screen was SNPH (Fig. 1b),
a molecule that arrests mitochondrial trafﬁcking at sites of
high-energy demands in neurons16. Although previously thought
of as ‘neuronal-speciﬁc’16, SNPH mRNA was expressed in non-
neuronal tissues (Supplementary Fig. 1b), as well as tumour and
non-transformed cell types (Supplementary Fig. 1c). To test the
relevance of this pathway, we next silenced SNPH mRNA
(Supplementary Fig. 1d) and protein (Supplementary Fig. 1e)
using multiple, independent small interfering RNA (siRNA) or
shRNA sequences. Depletion of SNPH constitutively increased
tumour cell invasion (Fig. 1d,e), and reversed the inhibition of
tumour cell invasion mediated by Gamitrinib (Supplementary
Fig. 1f,g), validating the shRNA screen. In control experiments,
cell proliferation over the course of the invasion was unaffected
(shRNA) or modestly reduced (siRNA) by SNPH silencing
(Supplementary Fig. 1h), and total mitochondria mass per cell
was not affected (Supplementary Fig. 1i). In complementary
experiments, stable or transient transfection of tumour cells with
SNPH cDNA (Supplementary Fig. 1j) suppressed tumour cell
invasion (Fig. 1e).
SNPH regulation of membrane dynamics of cell motility. We
next looked at the requirements of SNPH regulation of tumour
cell motility. In these experiments, depletion of SNPH by siRNA
(Fig. 1f, Supplementary Fig. 2a) or shRNA (Supplementary
Fig. 2b) increased FA complex dynamics (Fig. 1f, Supplementary
Fig. 2a,b), a prerequisite of cell movements11. This was associated
with decreased number of stable FA complexes, and increased
formation of new and decayed complexes (Fig. 1g, Supplementary
Fig. 2c). As analysed in two independent tumour cell types, SNPH
depletion resulted in overall increased number of dynamic FA
complexes (Supplementary Fig. 2d), whereas the total number of
FA complexes per cell was not affected (Supplementary Fig. 2e).
Consistent with increased FA complex dynamics, silencing
of SNPH potently stimulated tumour chemotaxis (Fig. 1h,
Supplementary Fig. 3a). This response was associated with
faster speed of cell migration (Supplementary Fig. 3b), and
greater distance travelled per cell (Supplementary Fig. 3c),
without affecting the directionality of cell movements
(Supplementary Fig. 3d). Reconstitution of SNPH-depleted cells
with siRNA-insensitive SNPH cDNA restored SNPH levels
(Supplementary Fig. 3e) and reversed the increase in tumour
chemotaxis (Supplementary Fig. 3f), with suppression of both
speed of cell migration (Fig. 1i), and distance travelled per cell
(Supplementary Fig. 3g).
SNPH regulation of mitochondrial dynamics. Mitochondrial
trafﬁcking to the cortical cytoskeleton has been proposed as a
‘spatiotemporal’ energy source to power tumour cell motility
and invasion8. Consistent with this model, depletion of SNPH
stimulated the repositioning of mitochondria from their
perinuclear localization to the cortical cytoskeleton of tumour
cells (Fig. 2a, Supplementary Fig. 4a). Comparable results were
obtained using mitochondria labelled with MitoTracker (Fig. 2b)
or Tom20 (Fig. 2c). Reconstitution of SNPH-depleted cells with
siRNA-insensitive SNPH cDNA prevented the increased
accumulation of mitochondria to the cortical cytoskeleton
(Fig. 2d, Supplementary Fig. 4b). Mitochondria in SNPH-
depleted tumour cells exhibited faster speed of movements
(Fig. 2e,f), higher processivity (time that mitochondria spend in
motion/time of analysis; Supplementary Fig. 4c) and greater
distance travelled (Fig. 2g,h, Supplementary Movie 1), compared
with control transfectants.
In addition to exaggerated mitochondrial trafﬁcking, loss of
SNPH was associated with increased mitochondrial dynamics in
tumour cells10 (Supplementary Fig. 5a, Supplementary Movie 2),
resulting in higher rates of both fusion and ﬁssion events (Fig. 3a,
Supplementary Fig. 5b–d). This inﬂuenced the speed of
subcellular mitochondrial trafﬁcking, as larger mitochondria
travelled at o0.05 mms 1, whereas smaller mitochondria
moved at up to 0.25 mms 1 (Fig. 3b). Consistent with
these ﬁndings, SNPH-depleted cells expressed higher levels
of mitofusins (MFN1, MFN2, mitochondrial fusion)
(Supplementary Fig. 5e), and increased recruitment of dynein-
related protein 1 (Drp1, mitochondrial ﬁssion) to mitochondria
(Supplementary Fig. 5f), compared with control. Mitochondrial
inner membrane fusion effector Opa1 was not affected
(Supplementary Fig. 5e), and Drp1 levels in the cytosol were
unchanged (Supplementary Fig. 5f). To test the functional
relevance of these ﬁndings, we next silenced MFN1 or MFN2
by siRNA (Supplementary Fig. 5g) in cells depleted of SNPH. In
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these experiments, depletion of either MFN proteins abolished
the increase in tumour cell invasion mediated by SNPH
knockdown (Fig. 3c, Supplementary Fig. 5h). Functionally,
expression of the antioxidant Peroxiredoxin-III (Prx-III)
prevented the increase in MFN1 levels induced by loss of
SNPH, whereas mitochondrial superoxide dismutase (SOD2) was
ineffective (Fig. 3d,e), and total mRNA levels of MFN1 or
MFN2 were unchanged in control or SNPH-depleted cells
(Supplementary Fig. 5i).
A SNPH network regulates tumour cell invasion. In neurons,
SNPH works in concert with a network of molecules that control
mitochondrial trafﬁcking (Fig. 3f)17, and a role of this network in
tumour cell movements was next investigated. siRNA silencing
of the anterograde kinesin KIF5B (also known as UKHC)
(Supplementary Fig. 6a) or atypical mitochondria-associated
Rho GTPase Miro 1 (Supplementary Fig. 6b, left) suppressed
the increased tumour cell invasion induced by loss of SNPH
(Fig. 3g, Supplementary Fig. 6c). In contrast, silencing of Miro2
(Supplementary Fig. 6b, right) did not reduce tumour cell
invasion in SNPH-knockdown cells (Fig. 3g, Supplementary
Fig. 6c). Next, we expressed various deletion mutants of
SNPH that lack the microtubule binding domain (DMBD),
kinesin-binding domain (DKBD), or LC8-binding domain
(DLBD) (Supplementary Fig. 6d), and looked at their effects on
tumour cell invasion. While expression of full length SNPH
suppressed tumour cell invasion (Fig. 3h), DMBD, DKB, or DLBD
mutants had no effect (Fig. 3h). Finally, we looked at the role of
the SNPH network on mitochondrial trafﬁcking induced by
cellular stress, including exposure of tumour cells to inhibitors
of the phosphatidylinositol-3 kinase (PI3K) pathway14. In these
experiments, siRNA silencing of KIF5B, Miro1 or Miro2 all
potently suppressed mitochondrial trafﬁcking to the cortical
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Figure 1 | SNPH regulation of tumour cell motility. (a) Schematic diagram of the genome-wide shRNA screening to identify novel mitochondrial
regulators of tumour cell invasion modulated by Gamitrinib. (b,c) Bioinformatics analysis of mitochondrial regulators of tumour cell invasion modulated by
Gamitrinib. (d,e) PC3 cells transfected with control siRNA (Ctrl) or SNPH-directed siRNA (top) or vector or SNPH cDNA (bottom) were analysed for
invasion across Matrigel-coated inserts. Representative micrographs of DAPI-stained cells (d) and quantiﬁcation of invaded cells (e). Data are represented
as mean±s.e.m. (n¼ 3). ***P¼0.0006–o0.0001 by Student’s t test. Scale bar, 200mm. (f) LN229 cells labelled with Talin-RFP and transfected with
control (Ctrl) or SNPH-directed siRNA were analysed for FA complex dynamics by time lapse microscopy. Representative merged frames at 0 h (magenta)
and 2 h (cyan) are shown. Scale bar, 5 mm. (g) FA complex dynamics in LN229 cells transfected with control siRNA or SNPH-directed siRNA (n¼ 380). (h)
LN229 cells were transfected with the indicated siRNAs and analysed for 2D chemotaxis by time-lapse video microscopy. Colour-identiﬁed cutoff velocities
of cell motility are indicated. Each tracing corresponds to an individual cell. Sample sizes were Ctrl (n¼60), SNPH (n¼ 89). (i) shRNA-transduced PC3
cells were reconstituted with vector or SNPH cDNA and analysed for cell motility in a 2D chemotaxis chamber with quantiﬁcation of speed of cell
migration. Data are represented as mean±s.e.m. Sample sizes were: pLKO,Vector (n¼46), SNPHsh,Vector (n¼48), SNPHsh,SNPHcDNA (n¼46).
*P¼0.0209; ***P¼0.0007 by one-way ANOVA and Bonferroni’s post-test.
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cytoskeleton (Fig. 3i, Supplementary Fig. 6e), as well as tumour
cell invasion (Supplementary Fig. 6f) induced by treatment with
the small molecule PI3K inhibitor, PX-866 (ref. 14).
In previous studies, mitochondrial trafﬁcking required energe-
tically active organelles14. Here, loss of SNPH was sufﬁcient to
deregulate this process, and resulted in robust mitochondrial
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Figure 2 | Mitochondrial trafﬁcking is modulated by SNPH. (a) LN229 cells transfected with control siRNA (Ctrl) or SNPH-directed siRNA were stained
with antibodies against Tom20, b-tubulin and DAPI and analysed by confocal microscopy. Top, 3D rendering of mitochondria localization by ﬂuorescence
microscopy. Bottom, 3D drawings represent the cells above, and show mitochondrial repositioning to the cortical cytoskeleton. Scale bar, 10mm. (b,c) Cells
were labelled with MitoTracker (b) or Tom20 (c) and analysed for mitochondrial recruitment to the cortical cytoskeleton. Symbols correspond to individual
cells. Data are represented as mean±s.e.m. **P¼0.003; ***Po0.0001 by Student’s t test. (d) PC3 cells transduced with the indicated shRNA were
transfected with vector or shRNA-insensitive SNPH cDNA and analysed for mitochondrial trafﬁcking to the cortical cytoskeleton. Symbols correspond to
individual cells. ***Po0.0001 by one-way ANOVA and Bonferroni’s post test. (e,f) Cells transfected with control or SNPH-directed siRNA and expressing
mitochondria-targeted RFP were imaged by time lapse microscopy, and individual mitochondria were tracked through the stack to calculate trafﬁcking
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recruitment to the cortical cytoskeleton in nutrient-starved
tumour cells (Supplementary Fig. 6g). Similar results were
obtained with oxidative phosphorylation-deﬁcient LN229 r0
cells, where SNPH depletion induced repositioning of
mitochondria to the cortical cytoskeleton, indistinguishably
from wild type LN229 cells (Supplementary Fig. 6h,i)14.
However, mitochondria from LN229 r0 cells depleted of SNPH
failed to support tumour chemotaxis, with negligible changes in
the speed of cell migration (Supplementary Fig. 6j), and overall
distance travelled by individual cells (Supplementary Fig. 6k).
SNPH is a novel metastasis suppressor. To examine the impact
of SNPH on tumour progression, we next inspected clinically
annotated public databases. We found that SNPH was mostly
downregulated in epithelial and haematologic malignancies,
compared with normal tissues (Fig. 4a). In contrast, Miro2 levels,
which support mitochondrial trafﬁcking (Fig. 3i, Supplementary
Fig. 6e) and tumour cell invasion (Supplementary Fig. 6f), were
typically upregulated in the same tumours (Fig. 4a). When
examined for disease outcome, loss of SNPH was an unfavourable
prognostic factor, correlating with shortened overall survival in
adenocarcinoma of the colon (Supplementary Fig. 7a) and lung
(Supplementary Fig. 7b).
To independently validate these results, we examined primary
patient samples in a universal cancer tissue microarray, by
immunohistochemistry. Consistent with the data above, SNPH
was expressed in normal breast epithelium, but downregulated
or undetectable in breast cancer (Fig. 4b,c), as well as
adenocarcinoma of the prostate (Supplementary Fig. 7c), colon
and lung (Supplementary Fig. 7d). Glioblastomas expressed high
levels of SNPH, compared with normal brain (Supplementary
Fig. 7d). When analysed in a series of clinically annotated breast
cancer patients (n¼ 324, Supplementary Table 2), SNPH levels
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were more prominently downregulated in the invasive front and
bulk (core) lesions, compared with ductal carcinoma in situ
(Fig. 4c). Histologic subtypes of HER2-enriched and basal-like
carcinoma also contained lower levels of SNPH than luminal A
or luminal B cases (Fig. 4d). SNPH expression in breast
cancer was independent of stage (Supplementary Fig. 7e) or
histotype (Supplementary Fig. 7f), but was signiﬁcantly more
downregulated in metastatic tumours to loco-regional lymph
nodes, compared with non-metastatic or low-metastatic cases
(Fig. 4e).
Based on these data, we next asked if SNPH inﬂuenced
metastasis in a mouse model of disseminated disease, in vivo8.
In these experiments, intrasplenic injection of PC3 cells stably
transfected with vector gave rise to extensive metastatic
dissemination to the liver 11 days after animal reconstitution
(Fig. 4f,g). In contrast, stable overexpression of SNPH in these
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Figure 4 | SNPH controls tumour progression and metastasis. (a) Bioinformatics analysis of SNPH or Miro2 differential expression in cancer versus
normal tissues in public databases (Oncomine, TCGA, Prognoscan). , upregulation; , downregulation; C/N, cancer/normal; HR, hazard ratio. (b) IHC
analysis of SNPH expression in breast carcinoma versus normal breast epithelium. Bulk, main lesion; IF, invasive front. Scale bar, 100 mm. (c) SNPH-positive
cells in normal breast, CIS, bulk breast carcinoma or invasive front (IF). Each point corresponds to individual patients. ***Po0.0001 by unpaired t test with
Welch’s correction. (d) SNPH-positive cells in molecular subtypes of breast cancer. Lum, luminal. HER2, HER2-enriched. Each point corresponds to
individual patients. **P¼0.006–0.007; *P¼0.01 by unpaired t test with Welch’s correction. (e) SNPH-positive cells in breast cancer with no lymph node
metastasis,p10% of metastatic lymph nodes (o10%) or410% metastatic lymph nodes (410%). Data are represented as mean±s.e.m. **P¼0.007 by
Mann Whitney test. (f) Histologic analysis of liver metastases after intrasplenic injection of PC3 cells stably expressing vector or SNPH cDNA. Scale bar,
500mm. (g) Number of liver metastatic foci per ﬁeld in animals from f. Data are represented as mean±s.e.m. (n¼ 15). ***Po0.0001 by Student’s t test.
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cells reduced the number (Fig. 4f,g), and size (Supplementary
Fig. 7g) of metastatic foci to the liver, lowering the overall
metastatic burden of reconstituted mice (Supplementary Fig. 7h).
Discussion
In this study, we have shown that tumours reprogram a network
of mitochondrial dynamics well characterized in neurons to fuel
cell motility, invasion and metastasis. This pathway is centred on
molecules that promote (Miro1/2, KIF5B) or suppress (SNPH)
the trafﬁcking of mitochondria to the cortical cytoskeleton
of tumour cells, a process that provides a concentrated,
‘spatiotemporal’ energy source to fuel membrane dynamics and
cell movements. As a negative regulator of this pathway, SNPH
acts as a conceptually novel ‘metastasis suppressor’, progressively
downregulated or lost during tumour progression, and associated
with heightened mitochondrial dynamics, increased tumour cell
invasion and shortened patient survival.
The role of mitochondrial bioenergetics in cancer has been
controversial. The pervasive glycolytic metabolism that is
hallmark of most malignancies2, and the characterization of
‘oncometabolites’ produced by a dysfunctional or mutant respir-
atory chain18 have suggested that mitochondrial metabolism may
be dispensable in malignancy, and may actually function as a
‘tumour suppressor’, at least in certain tumours19. It is now clear,
however, that oxidative phosphorylation remains an important
driver of tumour growth6, fuelling unique traits especially
important for disease progression. There is evidence that one of
these traits is tumour cell motility and metastasis8,9, but the
requirements of this response have been elusive, variously linked
in previous studies to aberrant ROS production20, increased fatty
acid metabolism21 or remodelling of oxidative phosphorylation
complexes22.
The data presented here suggest an alternative scenario,
where the coupling of mitochondrial bioenergetics to
mechanisms of organelle dynamics10 helps reposition
mitochondria to membrane protrusions of cell motility11,
fuelling chemotaxis and increased cell invasion14. Although this
process has been often considered ‘neuronal-speciﬁc’23, we now
know that mitochondria travel along the microtubule network
also in non-neuronal cells, supporting the motility of normal24, as
well as transformed13 cell types in response to stress conditions of
the microenvironment14.
Unlike neurons, where SNPH arrests mitochondrial
movements along the cytoskeleton16, tumour-associated SNPH
exhibited new functions in this process, reducing the speed
and distance travelled by individual mitochondria, and
suppressing cycles of mitochondrial ﬁssion and fusion, that is,
dynamics25. Mitochondrial dynamics has recently emerged
as a driver of malignancy10, contributing to oncogene-directed
transformation26, tumour progression27 and cell invasion28.
Using a novel algorithm that tracks quantitative changes in
mitochondrial morphology, we have shown here that loss of
SNPH heightened both fusion and ﬁssion events in tumour cells,
consistent with modulation of key effectors of organelle
dynamics, including increased expression of MFN1 and
recruitment of Drp1 to mitochondria10. Although this process
controlled the velocity of mitochondrial trafﬁcking, it is also
possible that SNPH modulation of dynamics couples to organelle
quality control mechanisms29, preventing the repositioning of
inactive or damaged mitochondria to the cortical cytoskeleton.
Consistent with this model, loss of SNPH was sufﬁcient to allow
recruitment of de-energized mitochondria from LN229 r0 cells14
to the cortical cytoskeleton, whereas silencing of MFN1 or MFN2
suppressed mitochondrial trafﬁcking and tumour cell invasion.
Initial structure–function studies presented here demonstrated
that specialized SNPH domains implicated in microtubule
binding, kinesin association or LC8 interaction17 were required
for mitochondrial trafﬁcking in tumour cells. In addition,
molecules known to regulate mitochondrial repositioning in
neurons, including KIF5B30 and Miro1 (ref. 24) emerged here as
novel modulators of organelle movements in the SNPH pathway
in tumours. Conversely, another atypical mitochondrial GTPase,
Miro2 (ref. 23) did not affect SNPH-dependent functions, but was
still required to support mitochondrial trafﬁcking induced by
cellular stress, that is, exposure to molecular therapy14. Together,
this suggests that Miro2 contributes to mitochondrial trafﬁcking
in transformed cells independently of SNPH, and this may be
important in vivo, as Miro2 levels are consistently increased in
disparate tumour types from bioinformatics analysis of public
databases.
A combination of quantitative cell motility and invasion
approaches in vitro, together with a mouse model of liver
metastasis that recapitulates key steps of disease dissemination
in vivo, established a role of SNPH as a conceptually novel
‘metastasis suppressor’. Consistent with this model, analysis of
public databases as well as primary breast cancer patients
demonstrated that SNPH levels are consistently downregulated
or lost during tumour progression, correlating with increased
metastasis, and shortened patient survival. The mechanism(s)
that titrate the levels of SNPH during tumour progression
remains to be elucidated. However, one possibility is that this
process hinges on changes in the tumour microenvironment,
which may force differential allocation of often limited resources
to support either cell proliferation or cell motility, but not both31.
Speciﬁcally, rising hypoxia and chronic nutrient deprivation, as
typically seen in advanced tumours32, may reprogram
mitochondrial dynamics through the SNPH pathway to support
heightened cell motility and ‘escape’ from an unfavourable
ecosystem33. This possibility is consistent with recent data that
mitochondrial metabolism is required to support tumour cell
motility under conditions of nutrient deprivation8, and that
cellular stress introduced by molecular therapy potently
stimulates mitochondrial trafﬁcking to the cortical cytoskeleton
and increased cell invasion14.
In sum, we have shown that tumours reprogram a neuronal
network of mitochondrial trafﬁcking and dynamics to control
metastatic competence. While these data reinforce a role of
mitochondrial metabolism as an important driver of tumour
progression4, molecules in the SNPH pathway exploited in
cancer, including KIF5B and Miro1 are druggable, opening fresh
therapeutic opportunities to oppose metastatic dissemination in
patients.
Methods
Antibodies and reagents. Antibodies to Drp1 (clone D6C7, Cell Signaling#8570
diluted 1:1,000), MFN1 (clone D6E2S, Cell Signaling#14739 diluted 1:1,000),
MFN2 (clone D2D10, Cell Signaling#9482 diluted 1:1,000), OPA1 (clone 18BD
BD Laboratories#612606 diluted 1:1,000), PrxIII (clone 4G10, Santa Cruz
Biotechnology sc-59663 diluted 1:1,000), SOD2 (clone D3X8F, Cell Signaling#
13141 diluted 1:1,000), SNPH (Sigma#HPA049393 diluted 1:1,000), SNPH (H-250,
Santa Cruz Biotechnology#sc-33824 diluted 1:500), KIF5B (Millipore#ABT405
diluted 1:1,000), Miro1 (RhoT1 A-8 Santa Cruz#sc-398520 diluted 1:200), Miro2
(RhoT2 H-45 Santa Cruz#sc-135387 diluted 1:500), FLAG (clone M-2,
Sigma#F1804 diluted 1:5,000) and b-actin (clone AC-15 Sigma#A5441 diluted
1:100,000) were used for Western blotting. Antibodies to paxillin (clone 5H11
Millipore/Upstate#05-417 diluted 1:100), a-tubulin (clone DM1A Sigma# T9026
diluted 1:200), Tom20 (FL-145Santa Cruz# sc-11415 diluted 1:250), SNPH
(Sigma#HPA049393 diluted 1:500) and anti-mitochondria antibody (MTC02
Abcam# ab3298 diluted 1:500) were used for immunoﬂuorescence. The small
molecule pan-PI3K inhibitor PX-866 was from LC Laboratories. The complete
chemical synthesis, HPLC proﬁle, and mass spectrometry of mitochondrial-
targeted Hsp90 small molecule antagonist and suppressor of oxidative
phosphorylation34, Gamitrinib has been reported15. The Gamitrinib variant
containing triphenylphosphonium as a mitochondrial-targeting moiety15 was used
for the shRNA screen at non-toxic concentrations. Mitotracker dyes, Phalloidin
Alexa Fluor 488, CellLight Talin-RFP BacMam 2.0, CellLight Mito-RFP BacMam
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2.0 and secondary antibodies for immunoﬂuorescence were from Molecular
Probes.
Cell culture. Human glioblastoma LN229, prostate epithelial (RWPE-1), prostate
adenocarcinoma (LNCaP, C4-2, DU145, PC3), breast epithelial (MCF10A), breast
adenocarcinoma (MDA-MB-231), human diploid ﬁbroblasts MRC-5 and mouse
ﬁbroblasts NIH3T3 were obtained from the American Type Culture Collection
(ATCC, Manassas, VA), and maintained in culture according to the supplier’s
speciﬁcations. Benign prostate hyperplasia (BPH1) cells were a generous gift from
Dr Simon W. Hayward (Vanderbilt University). A highly metastatic clone of PC3
with bone tropism (PC3-ML) was a generous gift from Dr Alessandro Fatatis
(Drexel University College of Medicine). Cell passaging was limited to o40
passages from receipt and cell lines were authenticated by STR proﬁling with
AmpFlSTR Identiﬁler PCR Ampliﬁcation Kit (Life Technologies) at the Wistar
Institute’s Genomics facility. Mycoplasma free-cultures were conﬁrmed at the
beginning of the studies, and every 2 months afterwards, by direct polymerase
chain reaction (PCR) of cultures using Bioo Scientiﬁc Mycoplasma Primer Sets
(cat#375501) and Hot Start polymerase (QIAGEN). Mitochondrial DNA-deﬁcient
LN229 r0 cells were described previously14 and maintained in culture medium
supplemented with 80 ngml 1 uridine and 1mM sodium pyruvate. Conditioned
media was prepared from exponentially growing cultures of NIH3T3 cells as
described four in DMEM supplemented with 4.5 g l 1 D-glucose, sodium pyruvate,
10mM HEPES and 10% FBS for 48 h. Where indicated, glucose starvation was
carried out for 24 h in DMEM without glucose supplemented with dialyzed FBS.
For experiments where cells were cultured oxidative medium (Gal medium),
DMEM without glucose was supplemented with 25mM D-(þ )-galactose and
dialyzed FBS.
shRNA genome-wide screening. A positive selection-based genome-wide screen
was carried out in duplicate by transducing PC3 cells with the pLKO.1 based-TRC
lentiviral shRNA library35,36. The 1 107 clones encoded by the library were
divided into 12 pools of B1,800 genes each, with an average of 5 clones per gene
(9,000 clones per pool). Cells were transduced with one lentiviral particle every 3
cells (m.o.i.¼ 0.3) at a representation of 1,000 cells per clone¼ 9 106 cells per
pool. Following 4 days of selection in the presence of 2 mgml 1 puromycin,
transduced cells were subject to treatment with Gamitrinib (5 mM, 16 h) and seeded
for invasion assays using Matrigel-coated 8 mm pore size six-well Transwells (BD)
at a density of 3.4 105 cells cm 2 of membrane. NIH3T3 medium was used as
chemoattractant. The following day, invasive cells were recovered by trypsinization
of the lower compartment of the transwell, and used for genomic DNA preparation
using QIAamp DNA Mini kit (QIAGEN), according to the manufacturer’s
protocol for cultured cells. Next, shRNAs were ampliﬁed from genomic DNAs,
cleaved into half-hairpins by digestion with XhoI and batch sequenced by Next
Generation Sequencing (NGS, see below).
Deconvolution and bioinformatics analysis of the shRNA screen. The shRNAs
inserted into the genomic DNA of invasive cells were ampliﬁed by PCR using the
strategy described35, except that the reverse primer was altered to have a one base
pair (bp) mutation of the XhoI site located in the pLKO.1 vector (extended data
Fig. 1a). With this modiﬁcation, XhoI digestion of the PCR product renders only
two fragments of 111 and 70 bp. The sequence of the primers used was Forward:
50-TGGCTTTATATATCTTGTGGAAAGGACGAAACACCG-30 and Reverse
(XhoI site mutated): 50-TGTGGATGAATACTGCCATTTGTCACGAGGTC-30.
PCR ampliﬁcation reactions were carried out starting with 12 mg of genomic DNA
from each pool with TaKaRa Ex Taq reagents (Clontech). PCR products (shRNA
hairpins) from the 12 pools of each sample were further combined, and digested
overnight with XhoI at 37 C. The 111 bp bands were puriﬁed from a 4% MetaPhor
agarose (Cambrex) gel. Five hundred ng of puriﬁed half-hairpin were used for
paired-end Illumina cDNA library preparation (TruSeq v.2). The libraries were run
on a Beckman Illumina HiSeq instrument producing 99,983,355 and 98,756,442
quality reads, and further processed for bioinformatics data analysis.
For bioinformatics analysis, samples were sequenced and processed using
custom script that inspected only reads with base call quality of at least 35 for
pattern [read start]TCGAG[21 bp-variable-insert] 50-CCGGTGTTTCGTCCTTTC
CACAAG-30 . Resulting inserts were mapped to ‘TRC shRNA Library Inventory
Flatﬁle’ (version from 5 April 2011) and the number of reads for each shRNA was
counted. Genes that had at least three shRNAs with at least 500 reads were
considered signiﬁcant in an experiment, and only genes that were signiﬁcant in
both experiments were considered for further analysis. Enrichment analysis of
candidate genes was done using DAVID software (https://david.ncifcrf.gov)
searching for overrepresentation of: gene ontology molecular functions, biological
processes and cellular components as well as swiss-prot functional keywords and
KEGG pathways. Results that passed false discovery rate o10% were called
signiﬁcant. Signiﬁcantly enriched related categories were grouped, and a general
group name was assigned and reported along with total number of unique genes
combined across all categories from the group, minimal P value and average false
discovery rate (Supplementary Table 1).
Plasmids andtransfections. True-ORF pCMV6-Entry-myc-Flag encoding SNPH
(cat# RC207749), SOD2 (cat# RC202330) and PrxIII (cat# RC205080) were from
Origene. SNPH mutants lacking the microtubule binding domain (DMTB,
D86-159 aa), LC8-binding domain (DLC8, D311-317 aa) or kinesin-binding
domain (DKBD, D337-422 aa) were generated with the Stratagene QuikChange II
XL Site-Directed Mutagenesis Kit (Agilent Technologies), and conﬁrmed by DNA
sequencing. Cells were transfected with 2 mg of pcDNA plus 4 ml X-treme gene
HP (Roche) for 24 h in complete medium, washed and subject to the indicated
treatments. Cells stably expressing full length SNPH, SNPH mutants or an empty
vector were generated by transfection of plasmids, followed by a 2-week selection in
the presence of 1mgml 1 G418 (Geneticin).
Gene silencing. Gene knockdown experiments by siRNA were carried out as
described8. The following sequences were used: control, non-targeting siRNA
pool (Dharmacon, D-001810) or speciﬁc siRNA pools targeting SNPH (either
Dharmacon L-020417 or Santa Cruz sc-41369), KIF5B (Santa Cruz, sc-36777),
Miro1 (Santa Cruz, sc-93809), Miro2 (Santa Cruz, sc-93029), Mfn1 (Santa Cruz
sc-43927) or Mfn2 (Santa Cruz sc-43928). Tumour cells were transfected with
the individual siRNA pools at 30–60 nM concentration in the presence of
Lipofectamine RNAiMAX (Invitrogen) at a 1:1 ratio (vol siRNA 20 mM:vol
Lipofectamine RNAiMAX). After 48 h, transfected cells were validated for target
protein knockdown by Western blotting or qPCR, and processed for subsequent
experiments. Alternatively, three independent shRNA sequences were used for
targeting the 30UTR of human SNPH: TRCN 0000147900, TRCN 0000128545 and
TRCN 0000150197 (Wistar Molecular Screening Facility). An empty pLKO-based
lentivirus was used as control. PC3 cells stably expressing shRNA targeting SNPH
were generated by infection with lentiviral particles, followed by a 2-week selection
in the presence of puromycin at 2 mgml 1.
Protein analysis. For Western blotting, protein lysates were prepared in 20mM
Tris HCl, pH 7.5, 137mM NaCl, 1% Triton X-100, 10% glycerol containing
EDTA-free Protease Inhibitor Cocktail (Sigma) and Phosphatase Inhibitor Cocktail
PhosStop (Roche), sonicated and precleared by centrifugation at 14,000g for 10min
at 4 C. Equal amounts of protein lysates were separated by SDS gel electrophoresis,
transferred to polyvinylidene diﬂuoride membranes, blocked in 5% low fat milk
diluted in TBST buffer (20mM Tris HCl, pH 7.5, 150mM NaCl, 0.1% Tween-20),
and further incubated with primary antibodies diluted in 5% BSA/TBST for 18 h at
4 C. For SNPH (Sigma#HPA049393), membranes were incubated with primary
antibody diluted 1:1,000 in 5% low fat milk diluted in TBST for 1 h at 22 C. For
detection of b-actin (clone AC-15 Sigma#A5441) membranes were incubated with
primary antibody diluted 1:100,000 in 5% BSA diluted in TBST for 30min at 22 C.
After washing in TBST, membranes were incubated with HRP-conjugated
secondary antibodies (1:1,000–1:5,000 dilution in 5% BSA/TBST) for 1 h at 22 C,
washed with TBST and protein bands were visualized by enhanced chemilumi-
nescence. Full blots from main and Supplementary Figs are shown in
Supplementary Fig. 8.
mRNA analysis. Relative mRNA levels of SNPH were determined by qPCR. RNA
was extracted with PureLink RNA Mini Kit (Life Technologies) following the
in-column DNA digestion protocol. Alternatively, RNA from eight normal human
tissues was obtained from BioChain and digested with RNAse-free DNAseI
(Thermo Scientiﬁc). Two mg of RNA were reversed transcribed using random
hexamers for 1 h at 37 C using the TaqMan High-Capacity cDNA Reverse
Transcription Kit (Life Technologies#4368814). One ml of cDNA diluted 1:5 was
used as template for qPCR reactions with TaqMan Gene Expression (GEX) assays
to detect the various transcripts in a ABI7500 Fast Real Time PCR system. The
following GEX assays were obtained from TaqMan (Life Technologies): SNPH
(Hs00920132_m1), MFN1 (Hs00966851_m1), MFN2 (Hs00208382_m1).
ACTB (Hs99999903_m1) and GAPDH (Hs99999905_m1) assays were used as
endogenous control to normalize the levels of mRNA across samples. The relative
abundance of mRNA was calculated according to the DDCt method.
Mitochondria time-lapse microscopy. Cells (4 104) growing in high optical-
quality glass bottom 35-mm plates (MatTek Corporation) were transduced with
Mito-RFP BacMam virus (50 particles per cell) for 18 h, then with Tubulin-GFP
BacMam virus (Life Technologies) (50 particles per cell) for 18 h, washed and
imaged with a  63 1.40 NA oil objective on a Leica TCS SP8 X inverted laser
scanning confocal microscope. Short duration time-lapse sequences were carried
out in a Tokai Hit incubation chamber equilibrated to 37 C and 5% CO2 with
bidirectional scanning at 8,000Hz using a resonant scanner. Time lapse was
performed at 10 s per frame for 1,000 s (LN229), or 1 s per frame for 300 s (PC3).
Individual 12-bit images were acquired using a white-light supercontinuum laser
(2% at 557 nm and 5% at 488 nm) and HyD detectors at  3 digital zoom with a
pixel size of 120 nm 120 nm. A pinhole setting of 3 Airy Units provided a section
thickness of 2.042 microns. At least 15 single cells per condition were collected
from three independent experiments.
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Analysis of mitochondria trafﬁcking. Time-lapse sequences were imported into
FIJI and individual mitochondria were manually tracked using the Manual
Tracking plugin. Mitochondria were tracked along the stacks until a fusion event
prevented continued tracking. The speed and distance between frames were used to
calculate the mean speed and cumulative distance travelled by each individual
mitochondria. Processivity was deﬁned as the proportion of time mitochondria
spent in motion relative to the total time of tracks and calculated based on the
frame-to-frame data for speed. Any given frame with speed a0 was considered as
‘in motion’. Based on processivity, mitochondria were further classiﬁed into high
processivity (470% of time spent in motion) or low processivity (o70% of time
spent in motion).
Computational detection of ﬁssion and fusion events. Computational image
analysis tasks to quantify mitochondrial dynamics included image denoising,
organelle segmentation and multi-target tracking. The denoising algorithm used a
model-based approach, combining a low-pass ﬁlter (diameter of 9 pixel) to remove
slow varying background with a median ﬁlter (diameter of 5 pixels) to remove
high-frequency shot noise. This approach was originally proposed for protein
localization37, and later applied to images of synthetic organelle data38 and
three-dimensional (3D) multi-channel time-lapse images showing stem cell
proliferation39. The mitochondrial segmentation algorithm combined the detection
of intensity peaks on the denoised image with a thresholded foreground region
obtained from an adaptive Otsu transform38,40. The peaks within the foreground
regions identify mitochondrial locations, whereas the connected component of
foreground pixels associated with each mitochondrial peak provide the size of the
individual or aggregate mitochondria to be tracked.
The applied tracking algorithm solved the data association problem between
pairs of frames in a technique based on the Hungarian assignment algorithm,
an approach originally developed for tracking endosomes in live-cell imaging41.
More advanced tracking algorithms that solve the data association problem over
multiple image frames simultaneously40,42 were less effective for this data set due to
the frequent ﬁssion and fusion events. The single parameter required by the
tracking algorithm is maximal mitochondrial velocity, empirically estimated at
0.32 mms 1 (25 pixels per frame). Following tracking, tracks of length shorter than
an empirically determined threshold of three image frames were removed.
Fission and fusion events were identiﬁed from the tracking results by
identifying conditions where a mitochondria track either ends (fusion) or appears
(ﬁssion) in a spatiotemporal region that enables associating that track with another
existing track. The number of ﬁssion and fusion events in each image frame were
normalized to the number of foreground mitochondrial pixels to allow comparison
of ﬁssion and fusion events among cells of different size and mitochondrial volume.
These normalized counts were treated as a sample of a random variable, and
compared between SNPH and control populations using non-parametric two
sample Kolmogorov–Smirnov tests for differences of distribution, and Wilcoxon
rank sum tests for differences of medians.
Focal Adhesion dynamics. Analysis of FA dynamics was carried out as
described14. Cells growing in high optical quality 35-mm glass bottom plates
(MatTek Corporation) were transduced with Talin-RFP BacMam virus
(50 particles per cell) for 18 h and imaged with a  40 objective on a Leica SP8
confocal microscope. The atmosphere was equilibrated to 37 C and 5% CO2 in an
incubation chamber. Time-lapse microscopy was carried out for the indicated time
intervals at 3min per frame. Sequences were imported into ImageJ for further
analysis. The initial and ﬁnal frames were duplicated and assembled as composite
images. FA complexes were manually counted and classiﬁed (according to the
presence in some or all of the time frames) into four groups: decaying, newly
formed, stable sliding (FA moves to a different position over time) and stable
mature (merged areas). The rate of decay and assembly of FA complexes was
calculated for each cell as the number of FA changing per hour. At least 200 FA
complexes from 10 cells were analysed from 5 to 10 independent time-lapse
videomicroscopy experiments per condition.
Immunoﬂuorescence. Tumour cells under the various conditions tested were
ﬁxed in formalin/PBS (4% ﬁnal concentration) for 15min at 22 C. Cells were then
permeabilized with 0.1% Triton X-100/PBS for 5min, washed, and incubated in 5%
normal goat serum (NGS, Vector Labs) diluted in 0.3M glycine/PBS for 60min.
Primary antibodies against paxillin (diluted 1:100), Tom20 (diluted 1:300),
a-tubulin (diluted 1:200) or MTC02 (diluted 1:500) were added in 5% NGS/0.3M
glycine/PBS and incubated for 18 h at 4 C. After three washes in PBS, secondary
antibodies conjugated either to Alexa488, TRITC or Alexa633 were diluted 1:500 in
5% NGS/0.3M glycine/PBS and added to cells for 1 h at 22 C. Where indicated,
F-actin was stained with phalloidin Alexa488 (1:200 dilution) for 30min at
22 C. Slides were washed and mounted in 4,6-diamidino-2-phenylindole
(DAPI)-containing Prolong Gold mounting medium (Life Techonologies). At least
seven random ﬁelds were analysed by ﬂuorescence microscopy in a Nikon i80
microscope.
Cortical mitochondria and total mitochondria mass quantiﬁcation.
Mitochondria/F-actin composite images were analysed in ImageJ as described14.
Brieﬂy, the F-actin channel was used to manually label the cell boundary and a belt
extending from the boundary towards the inside of the cell was marked as the
‘cortical mask’. This cortical mask was subsequently applied to the mitochondria
channel to measure intensity at the cortical region, and normalized to total
mitochondria intensity per cell and cell area. A minimum of 30 cells were analysed
in each independent experiment to obtain mean values. For quantiﬁcation of total
mitochondrial mass, composite images were analysed in ImageJ. The cell border
was manually traced on the F-actin channel and this ‘cell mask’ was subsequently
applied to the mitochondria channel to measure total mitochondria signal per cell.
Maximum intensity was monitored to ensure no pixel saturation (for example, max
intensity o256 for 8-bit images). Mitochondria mass was normalized to total cell
area. A minimum of 30 cells were analysed in each independent experiment to
obtain mean values. As a second independent method to determine mitochondria
mass, 2 104 cells plated in quadruplicate on 96-MW plates were labelled 1 h at
37 C with 50 nM Mitotracker Green FM (Life Technologies), washed and green
ﬂuorescence was read in a multiplate reader using a FITC ﬁlter. Mitochondria mass
(green ﬂuorescence) per well was normalized to total cell number.
Mitochondrial isolation. Mitochondrial fractions were prepared using a
mitochondrial isolation kit for cultured cells (ThermoFisher). Brieﬂy, cells were
homogenized by 70 strokes using a Dounce Grinder in isolation buffer A plus
protease inhibitor cocktail. Cell extracts were collected into equal volumes of
isolation buffer C with buffer A. Cell debris and nuclei were removed by
centrifugation at 700g for 10min, and mitochondrial fractions were collected by
centrifugation at 3,000g for 25min.
Two-dimensional tumour cell chemotaxis. Experiments were carried out as
described14. Brieﬂy, 1 104 cells were seeded in two-dimensional (2D) chemotaxis
chambers (Ibidi) in complete medium. After 6 h attachment, cells were washed and
the reservoirs were ﬁlled with serum-free medium supplemented with 0.1% BSA,
followed by gradient setup using NIH3T3 conditioned medium. Videomicroscopy
was performed over 10 h, with a time-lapse interval of 10min. Stacks were
imported into Image J for analysis. Images were aligned according to subpixel
intensity registration with the StackReg plugin for Image J43. At least 30 cells were
tracked using the Manual Tracking plugin for Image J, and the tracking data from
four independent time-lapse experiments were pooled and exported into the
Chemotaxis and Migration Tool v2.0 (Ibidi) for graphing and calculation of mean
and s.d. of speed, accumulated distance and Euclidean distance of movement.
Tumour cell invasion. Experiments were carried out essentially as described8
using Growth Factor Reduced Matrigel-coated 8 mm PET transwell chambers
(Corning). Tumour cells were seeded in duplicates onto the coated transwell ﬁlters
at a density of 0.5–1 105 cells per well in medium containing 0.8% FBS, and
conditioned media from NIH3T3 was placed in the lower chamber as
chemoattractant. Cells were allowed to invade for 16–24 h, non-invading cells were
scraped off the top side of the membranes and the invasive cells on the transwell
insert were ﬁxed in methanol. Membranes were mounted in medium containing
DAPI (Vector Labs) and analysed by ﬂuorescence microscopy. Five random ﬁelds
at  20 magniﬁcation were collected for each membrane. Digital images were
batch imported into ImageJ, thresholded and analysed with the Analyze particles
function. Experiments were repeated three times. Where indicated, cell
proliferation was assayed under identical conditions by a CellTiter 96 AQueous
One Solution Cell Proliferation Assay or by direct counting of cells.
Immunohistochemistry. Immunohistochemical (IHC) detection of SNPH
was performed on breast cancers and Cancer Universal Tissue Microarrays
(CaU-TMAs) as described previously44. Brieﬂy, 4 mm thick slides were incubated
for 1 h with a rabbit polyclonal anti-SNPH antibody (Sigma#HPA049393 diluted
1:300). IHC was performed using an automatic stainer (Benchmark ULTRA,
Ventana), with detection of antibody reactivity with a kit using peroxidase-
diaminobenzidine as the chromogen (DAB UltraView, Ventana). All slides were
counterstained with hematoxylin. As negative control, one slide was processed
without the primary antibody. Since SNPH staining intensity was homogeneous
among different samples types, IHC scores were attributed considering only the
percentage of stained normal or tumour cells in each core (range 0–100%).
Animal studies. Studies were carried out in accordance with the recommenda-
tions in the Guide for the Care and Use of Laboratory Animals of the National
Institutes of Health (NIH). Protocols were approved by the Institutional Animal
Care and Use Committee (IACUC) of The Wistar Institute. Experiments were
done without randomization, and without blinding. Sample size was determined by
power analysis. All animals were included in the analysis. A liver metastasis model
was performed essentially as described8. Surgical procedures were carried out in
isoﬂurane-anaesthetised animals following aseptic technique inside a biosafety
cabinet, and a slow release Buprenorphine formulation was administered for pain
relief. PC3 cells at 80% conﬂuency were suspended in PBS, and 50 ml containing
1 106 cells were injected intrasplenically in anaesthetised 6–8 weeks old male
NOD SCID g (NSG, NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) mice (Jackson Laboratory).
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Spleens were removed 24 h after injection to minimize potentially confounding
effects on metastasis due to variable growth of primary tumours. Animals (three
per group) were euthanized 11 days after injection, and livers were resected,
ﬁxed in formalin and parafﬁn embedded. Serial liver sections 500 mm apart (n¼ 15
per each condition) were stained with hematoxylin and eosin and analysed
histologically. Metastatic foci were quantiﬁed by morphometry and expressed as
number of lesions and surface areas of tumour growth compared with total surface
area, as described8.
Patients. Breast cancer tissues from 324 female patients who underwent curative
surgery at Fondazione IRCC Ca’ Granda between 2004 and 2008 were retrieved
from the archives of the Division of Pathology. The study was approved by an
Institutional Review Board at Fondazione IRCCS Ca’ Granda Ospedale Maggiore
Policlinico Milan, Italy (approval no. 179/2013). Informed consent was obtained
from all subjects. Representative cores of normal mammary glands (n¼ 114),
carcinoma in situ lesions (CIS, n¼ 79), as well as of tumour bulk (core lesion) and
invasive front (IF, n¼ 299) were arranged in tissue microarrays as previously
described44. The patients’ clinicopathological features according to the American
Joint Committee on Cancer -AJCC- TNM system are summarized in
Supplementary Table 2. Breast cancer metastatic burden to lymph nodes was
calculated as the proportion of metastatic nonsentinel lymph nodes over the total
number of analysed lymph nodes. The value of 10% was chosen as cutoff for high
metastatic burden (Met LN410%).
Breast cancer molecular subtypes were determined by IHC assays of ER, PR,
HER2 and Ki67 markers performed at diagnosis following the 2011 St Gallen
guidelines45,46. Data were available for 321 patients (99%), who were therefore
classiﬁed as luminal A (n¼ 182), luminal B-HER2 negative (n¼ 95), basal-like
(n¼ 40), or HER2-enriched (n¼ 4) subtypes. For a subgroup of breast cancer
patients (n¼ 10), DNA-free total RNA was available from normal, CIS, tumour
bulk and invasive front lesions. These samples were investigated for presence of
SNPH isoforms by PCR on retrotranscribed cDNA. A Cancer Universal Tissue
Microarray (CaU-TMA) platform has been described21,44.
Statistical analyses. Unless otherwise stated, all experiments were carried out in
triplicates and repeated at least thrice (n¼ 3). For single cell analyses, the sample
sizes are indicated in each ﬁgure and represent the cumulative n from a minimum
of three independent experiments or time lapses. For descriptive data analysis,
means, s.d. and medians were calculated, and distributions of data were examined
to ascertain whether normal theory methods were appropriate. Student’s t-test or
Wilcoxon rank sum test was used for two-group comparative analyses. For
multiple-group comparisons, ANOVA or Kruskal–Wallis test with post-hoc
Bonferroni’s procedure were applied. Variance similarity between groups was
tested with Fisher (two groups) or Bartlett’s (multiple groups) tests. All statistical
analyses were performed using GraphPad software package (Prism 6.0) for
Windows. A P value of o0.05 was considered as statistically signiﬁcant.
Code availability. The custom software for segmenting and tracking mitochondria
can be downloaded from https://git-bioimage.coe.drexel.edu. The program codes
are provided free and open source, under the BSD license. To run the software,
MATLAB version 2015b or later is required.
Data availability. The data that support the ﬁndings of this study are available
from the corresponding author upon request.
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